Sucampo/Takeda’s Amitiza First To Fill Zelnorm Void In IBS Market

With the addition of an irritable bowel syndrome indication, Sucampo Pharmaceuticals has expanded the market opportunity for its chronic idiopathic constipation drug Amitiza by about 20 million patients